{
    "clinical_study": {
        "@rank": "107671", 
        "acronym": "TELEPATH", 
        "arm_group": [
            {
                "arm_group_label": "250 mg telotristat etiprate", 
                "arm_group_type": "Experimental", 
                "description": "One telotristat etiprate (250 mg) tablet administered three times daily"
            }, 
            {
                "arm_group_label": "500 mg telotristat etiprate", 
                "arm_group_type": "Experimental", 
                "description": "Two telotristat etiprate (250 mg) tablets administered three times daily"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this study is to evaluate the long-term safety and tolerability of\n      orally administered telotristat etiprate."
        }, 
        "brief_title": "Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms", 
        "condition": "Carcinoid Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoid Tumor", 
                "Malignant Carcinoid Syndrome", 
                "Serotonin Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Ongoing participation in a Phase 2 (LX1606.1-202-CS, LX1606.1-203-CS) or Phase 3\n             (LX1606.1-301-CS, LX1606.1-303-CS) study\n\n          -  Patients of childbearing potential must agree to use an adequate method of\n             contraception (defined as having a failure rate of <1% per year) during the study and\n             for 12 weeks after the Follow-up visit.\n\n          -  Ability and willingness to provide written informed consent\n\n        Exclusion Criteria:\n\n          -  Major protocol violations or tolerability concerns in a Phase 2 (eg, LX1606.1-202-CS,\n             LX1606.1-203-CS) or Phase 3 (eg, LX1606.1-301-CS, LX1606.1-303-CS) study\n\n          -  Positive pregnancy test\n\n          -  Presence of any clinically significant findings at entry for medical history,\n             laboratory values, or physical examination"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "160", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02026063", 
            "org_study_id": "LX1606.1-302-CS", 
            "secondary_id": "LX1606.302"
        }, 
        "intervention": {
            "arm_group_label": [
                "250 mg telotristat etiprate", 
                "500 mg telotristat etiprate"
            ], 
            "intervention_name": "Telotristat etiprate tablets (250 mg)", 
            "intervention_type": "Drug", 
            "other_name": "LX1606"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 2, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Iowa City", 
                        "country": "United States", 
                        "state": "Iowa", 
                        "zip": "52242"
                    }, 
                    "name": "Lexicon Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lexington", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40536"
                    }, 
                    "name": "Lexicon Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Lexicon Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bad Berka", 
                        "country": "Germany", 
                        "zip": "99437"
                    }, 
                    "name": "Lexicon Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "13353"
                    }, 
                    "name": "Lexicon Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Manchester", 
                        "country": "United Kingdom", 
                        "zip": "M204BX"
                    }, 
                    "name": "Lexicon Investigational Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Germany", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter, Long-term Extension Study to Further Evaluate the Safety and Tolerability of Telotristat Etiprate (LX1606)", 
        "overall_contact": {
            "email": "sjackson@lexpharma.com", 
            "last_name": "Shanna Jackson, Clinical Trial Manager", 
            "phone": "281-863-3484"
        }, 
        "overall_official": {
            "affiliation": "Lexicon Pharmaceuticals, Inc.", 
            "last_name": "Doug Fleming, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Germany: Federal Institute for Drugs and Medical Devices"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Incidence of treatment-emergent adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "50 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02026063"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "EORTC QLQ-C30 (a questionnaire developed to assess the quality of life of cancer patients) and GI.NET21 (module intended for use among patients with G.I.-related neuroendocrine tumours) quality of life questionnaires", 
            "measure": "Quality of Life measures", 
            "safety_issue": "No", 
            "time_frame": "Baseline and every 24 weeks"
        }, 
        "source": "Lexicon Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Lexicon Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}